Report cover image

Lennox-Gastaut Syndrome Treatment Market by Therapy Type (Non-Surgical Treatment, Surgery), Route of Administration (Oral, Parenteral), Distribution Channel, End Users - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 186 Pages
SKU # IRE18445441

Description

Lennox-Gastaut Syndrome Treatment Market by Therapy Type (Non-Surgical Treatment, Surgery), Route of Administration (Oral, Parenteral), Distribution Channel, End Users - Global Forecast 2024-2030


The Lennox-Gastaut Syndrome Treatment Market size was estimated at USD 643.29 million in 2023 and expected to reach USD 670.63 million in 2024, at a CAGR 5.28% to reach USD 922.38 million by 2030.

Global Lennox-Gastaut Syndrome Treatment Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Lennox-Gastaut Syndrome Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Lennox-Gastaut Syndrome Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Lennox-Gastaut Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amneal Pharmaceuticals Inc., Aquestive Therapeutics Inc., Bausch Health Companies Inc., Cision Ltd., Eisai Co. Ltd., GlaxoSmithKline PLC, GW Pharmaceuticals PLC, H. Lundbeck A/S, Johnson and Johnson, Lupin Ltd., Marinus Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd, Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., UCB SA, Upsher Smith Laboratories LLC, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Lennox-Gastaut Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Therapy Type
Non-Surgical Treatment
Intravenous Immunoglobulin Therapy

Ketogenic Diet Products

Surgery

Route of Administration
Oral

Parenteral

Distribution Channel
Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

End Users
Homecare

Hospitals

Specialty Clinics

Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam

Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Lennox-Gastaut Syndrome Treatment Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Lennox-Gastaut Syndrome Treatment Market?
3. What are the technology trends and regulatory frameworks in the Lennox-Gastaut Syndrome Treatment Market?
4. What is the market share of the leading vendors in the Lennox-Gastaut Syndrome Treatment Market?
5. Which modes and strategic moves are suitable for entering the Lennox-Gastaut Syndrome Treatment Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

186 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Lennox-Gastaut Syndrome Treatment Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising population with risk factors for LGS and need for treatment
5.1.1.2. Growing awareness of LGS by governments and global organizations
5.1.1.3. Rise in orphan drug designation
5.1.2. Restraints
5.1.2.1. Limitations in diagnosing LGS and high cost of treatment
5.1.3. Opportunities
5.1.3.1. Introduction of phytochemicals for LGS treatment
5.1.3.2. Technological advancements in the treatment of LGS
5.1.4. Challenges
5.1.4.1. Side effects associated with available treatment
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Lennox-Gastaut Syndrome Treatment Market, by Therapy Type
6.1. Introduction
6.2. Non-Surgical Treatment
6.3.1. Intravenous Immunoglobulin Therapy
6.3.2. Ketogenic Diet Products
6.3. Surgery
7. Lennox-Gastaut Syndrome Treatment Market, by Route of Administration
7.1. Introduction
7.2. Oral
7.3. Parenteral
8. Lennox-Gastaut Syndrome Treatment Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Lennox-Gastaut Syndrome Treatment Market, by End Users
9.1. Introduction
9.2. Homecare
9.3. Hospitals
9.4. Specialty Clinics
10. Americas Lennox-Gastaut Syndrome Treatment Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Lennox-Gastaut Syndrome Treatment Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.
10. South Korea
11.
11. Taiwan
11.
12. Thailand
11.
13. Vietnam
12. Europe, Middle East & Africa Lennox-Gastaut Syndrome Treatment Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.
10. Nigeria
12.
11. Norway
12.
12. Poland
12.
13. Qatar
12.
14. Russia
12.
15. Saudi Arabia
12.
16. South Africa
12.
17. Spain
12.
18. Sweden
12.
19. Switzerland
12.
20. Turkey
12.
21. United Arab Emirates
12.
22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. Amneal Pharmaceuticals Inc.
14.1.3. Aquestive Therapeutics Inc.
14.1.4. Bausch Health Companies Inc.
14.1.5. Cision Ltd.
14.1.6. Eisai Co. Ltd.
14.1.7. GlaxoSmithKline PLC
14.1.8. GW Pharmaceuticals PLC
14.1.9. H. Lundbeck A/S
14.1.
10. Johnson and Johnson
14.1.
11. Lupin Ltd.
14.1.
12. Marinus Pharmaceuticals Inc.
14.1.
13. Pfizer Inc.
14.1.
14. Sanofi SA
14.1.
15. Sun Pharmaceutical Industries Ltd
14.1.
16. Supernus Pharmaceuticals Inc.
14.1.
17. Teva Pharmaceutical Industries Ltd.
14.1.
18. UCB SA
14.1.
19. Upsher Smith Laboratories LLC
14.1.
20. Viatris Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. LENNOX-GASTAUT SYNDROME TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. LENNOX-GASTAUT SYNDROME TREATMENT MARKET DYNAMICS
FIGURE 7. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
FIGURE 8. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
FIGURE 14. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. LENNOX-GASTAUT SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us